1	New-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I, DPP4I
2	and GLP1a: A population-based cohort study
3	Oscar Hou In Chou MSc <sup>1*</sup> , Lei Lu, Ph.D. <sup>2*</sup> , Cheuk To Chung <sup>3</sup> , Jeffrey Shi Kai Chan
4	MBChB MPH <sup>3</sup> , Raymond Ngai Chiu Chan MBChB <sup>3</sup> , Athena Lee Yan Hiu <sup>3</sup> , Edward
5	Christopher Dee MD <sup>4</sup> , Kenrick Ng MB BChir MA MRCP PhD <sup>5,6</sup> , Hugo Hok Him Pui <sup>3</sup> ,
6	Sharen Lee MBChB <sup>3</sup> , Bernard Man Yung Cheung MB BChir PhD FRCP <sup>1</sup> , Gary Tse MD
7	PhD FRCP <sup>7, 8, 9</sup> , Jiandong Zhou PhD <sup>10^</sup>
8	
9 10 11 12 13 14 15	<ul> <li><sup>1</sup> Division of Clinical Pharmacology, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China</li> <li><sup>2</sup> Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom</li> <li><sup>3</sup> Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Hong Kong, China</li> <li><sup>4</sup> Department of Radiation Oncology, Memorial Sloan Kettering Cancer, New York, United</li> </ul>
16	States
17	<sup>5</sup> Department of Medical Oncology, University College London Hospital, London, UK.
18	<sup>6</sup> Department of Medical Oncology, St Bartholomew's Hospital, London, UK
19 20 21 22 23 24 25 26 27 28 29 30	<ul> <li><sup>7</sup> School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China</li> <li><sup>8</sup> Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China</li> <li><sup>9</sup> Kent and Medway Medical School, Canterbury Christ Church University and University of Kent, Canterbury, United Kingdom</li> <li><sup>10</sup> Division of Experimental Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom</li> </ul>
31	* Co-first author
32	^ Correspondence to:
33	Jiandong Zhou, Ph.D.
34	Division of Experimental Medicine, Nuffield Department of Medicine, University of Oxford,
35	Oxford, United Kingdom
36	Email: jiandong.zhou@ndm.ox.ac.uk
37	
38	
39	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 40 Abstract

41 **Background:** Sodium-glucose cotransporter 2 inhibitors (SGLT2I) have been suggested to 42 reduce new-onset cancer amongst type-2 diabetes mellitus (T2DM) patients. 43 **Objective:** This real-world study aims to compare the risks of prostate cancer between 44 SGLT2I and dipeptidyl peptidase-4 inhibitors (DPP4I) amongst T2DM patients. 45 **Design, setting and participants:** This was a retrospective population-based cohort study of 46 prospectively recorded data on type-2 diabetes mellitus (T2DM) male patients prescribed either SGLT2I or DPP4I between January 1st 2015 and December 31st 2020 from Hong 47 48 Kong. 49 Methods: The primary outcome was new-onset prostate cancer. The secondary outcomes 50 included cancer-related mortality and all-cause mortality. Propensity score matching (1:1 51 ratio) using the nearest neighbour search was performed and multivariable Cox regression 52 was applied to compare the risk. A three-arm sensitivity analysis including the glucagon-like 53 peptide-1 receptor agonist (GLP1a) cohort was conducted. 54 **Results:** This study included 42129 male T2DM patients (median age: 61.0 years old [SD: 12.2]; SGLT2I: n=17120; DPP4I: n=25009). After matching, the number of prostate cancers 55 56 was significantly lower in SGLT2I users (n = 60) than in DPP4I (n = 102). SGLT2I use was associated with lower prostate cancer risks (HR: 0.45; 95% CI: 0.30-0.70) after adjustments 57 58 than DPP4I. The results remained consistent in the sensitivity analysis. SGLT2I reduced the 59 risks of prostate cancer prominently amongst patients who were older (age >65), patients 60 with 2<sup>nd</sup> and 3<sup>rd</sup> quartile of HbA1c, concurrent metformin uses, and concurrent sulphonylurea 61 uses. SGLT2I was associated with higher risks of prostate cancer amongst sulphonylurea 62 non-users.

- 63 Conclusion: The real-world study demonstrated SGLT2I was associated with lower risks of
- 64 new-onset prostate cancer after matching and adjustments compared to DPP4I. This result
- 65 warrants further prospective studies.

66

- 67 Keywords: Sodium-glucose cotransporter 2 inhibitors; Dipeptidyl peptidase-4 inhibitors;
- 68 Glucagon-like peptide-1 receptor agonist; Prostate; Prostate cancer

## 69



# 71

72 Graphical abstract

## 73 Introduction

74 Type 2 diabetes mellitus (T2DM) and prostate cancer are two of the most common chronic diseases that are affected by the ageing male population [1, 2]. Despite relatively lower 75 rates of prostate cancer in Asia compared to Northern America, there have been increasing 76 77 incidence rates in several Asian countries, which is potentially related to the rising prevalence 78 of obesity, metabolic aberrations and T2DM [3, 4]. The current literature suggests an 79 association between T2DM and cancer proliferation, however its influence on the development of prostate cancer remains controversial [5]. This notwithstanding, there is also evidence 80 81 suggesting that SGLT2I demonstrate a protective effect against new-onset overall cancer compared to DPP4I [6]. This has sparked interest in inquiring whether better diabetic 82 83 management can reduce the risk of prostate cancer via existing anti-diabetic medications. 84 Subsequently, this may allow clinicians to consider alternative treatment options for those at 85 risk of prostate cancer.

86 Previous results regarding the association of prostate cancer and metformin use remains 87 controversial [7-10]. This further propagated research on novel anti-diabetic agents such as sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase 4 inhibitors 88 89 (DPP4I) on prostate cancer; as these drugs are the novel second line anti-diabetic medication 90 commonly prescribed in Hong Kong and other developed countries. Previous studies has 91 shown that the inhibition of SGLT2-mediated glucose uptake could reduce the proliferation of 92 prostate cells molecularly [11]. Meanwhile, the clinical data on SGLT2I remained scarce. For 93 direct comparison between the SGLT2I and DPP4I usage in the clinical setting, a study found 94 no significant difference in risk of prostate cancer [12]. As of now, there is limited clinical 95 evidence surrounding the association of SGLT2I and DPP4I on prostate cancer. This present 96 study aims to investigate the role of SGLT2I and DPP4I with new-onset prostate cancer in a 97 cohort of T2DM patients from Hong Kong.

98

#### 99 Methods

#### 100 Study population

101 This study was approved by the Institutional Review Board of the University of Hong 102 Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250) and 103 complied with the Declaration of Helsinki. This was a retrospective population-based study of 104 prospectively collected electronic health records using the Clinical Data Analysis and 105 Reporting System (CDARS) by the Hospital Authority (HA) of Hong Kong. The records cover 106 both public hospitals and private clinics in Hong Kong. It was verified that over 90% of the 107 identified T2DM patients were under the HA [13, 14]. This system has been used extensively 108 by our teams and other research teams in Hong Kong. The system contains data on disease 109 diagnosis, laboratory results, past comorbidities, clinical characteristics, and medication 110 prescriptions. The system has been used by our Hong Kong research team to perform 111 comparative studies [9, 15, 16]. T2DM patients who were administered with SGLT2I or DPP4I 112 in centres under the Hong Kong HA, between January 1st, 2015, to December 31st, 2020, were 113 included. The glucagon-like peptide-1 receptor agonist (GLP1a) cohort was included for 114 sensitivity analysis to demonstrate the relative effects amongst the second line oral anti-diabetic 115 agents.

116

117

118 *Predictors and variables* 

Patients' demographics include gender and age of initial drug use (baseline), clinical and biochemical data were extracted for the present study. Prior comorbidities were extracted in accordance with the *International Classification of Diseases Ninth Edition* (ICD-9) codes (**Supplementary Table 1**). The diabetes duration was calculated by examining the earliest date

123 amongst the first date of (1) diagnosis using of ICD-9; (2) Hba1c  $\geq 6.5\%$ ; (3) Fasting glucose 124 >= 7.0 mmol/l or Random glucose 11.1 mmol/l 4 Using anti-diabetic medications. The number 125 of hospitalisations in the year prior the index days were extracted. The Charlson's standard 126 comorbidity index was calculated [17]. The prostate medication (alpha-blockers), 127 cardiovascular medications, anti-diabetic agents, and were extracted from the database. The 128 duration and frequency of SGLT2I and DPP4I usage were calculated. The baseline laboratory 129 examinations, including the glucose profiles and renal function tests were extracted. The 130 microbiology testing results were also extracted to define the urinary tract infection 131 (Supplementary Table 1). The estimated glomerular filtration rate (eGFR) was calculated using the abbreviated modification of diet in renal disease (MDRD) formula [18]. The 132 133 following patient groups were excluded: those who (1) with prior prostate cancer (n=135); (2) died within 30 days after initial drug exposure (n=167); (3) without complete demographics 134 135 (n=11); (4) under 18 years old (n=29); (5) new onset prostate cancer development less than 1 136 year after drug exposure (n=20) (Figure 1). To account for the incomplete laboratory data, the 137 multiple imputation by chained equations was performed according to the previous published 138 study [19].

139

140 *Study outcomes* 

The primary outcome of this study was new-onset prostate cancer (ICD9: 185) after the index date of the drug use. The secondary outcomes were cancer-related mortality and all-cause mortality. Mortality data were obtained from the Hong Kong Death Registry, a populationbased official government registry with the registered death records of all Hong Kong citizens linked to CDARS. Mortality was recorded using the *International Classification of Diseases Tenth Edition* (ICD-10) coding. The as-treat approach was adopted which patients were censored at treatment discontinuation or switching of the comparison medications. The

endpoint date of interest for eligible patients was the event presentation date. The endpoint for
those without primary outcome was the mortality date or the end of the study period (31<sup>st</sup>
December 2020).

151

152 *Statistical analysis* 

153 Descriptive statistics are used to summarize baseline clinical and biochemical 154 characteristics of patients with SGLT2I and DPP4I use. For baseline clinical characteristics, 155 continuous variables were presented as mean (95% confidence interval/standard deviation [SD]) 156 and the categorical variables were presented as total numbers (percentage). Propensity score 157 matching generated by logistic regression with 1:1 ratio for SGLT2I use versus DPP4I use 158 based on demographics, number of prior hospitalization, non-SGLT2I/DPP4I medications, 159 number of prior anti-diabetic drugs, prior comorbidities, renal function, duration from T2DM 160 diagnosis initial drug exposure, HbA1c and fasting glucose were performed using the nearest 161 neighbour search strategy with a calliper of 0.1. Propensity score matching was performed 162 using Stata software (Version 16.0). Baseline characteristics between patients with SGLT2I 163 and DPP4I use before and after matching were compared with absolute standardized mean 164 difference (SMD), with SMD<0.10 regarded as well-balanced between the two groups.

165 The cumulative incidence curves for the primary outcomes and secondary outcomes 166 were constructed. Proportional Cox regression models were used to identify significant risk 167 predictors of adverse study outcomes, with adjustment for demographics, comorbidities, 168 number of prior hospitalisations, medication profile, renal function, glycaemic tests, and the 169 duration of T2DM. The log-log plot was used to verify the proportionality assumption for the 170 proportional Cox regression models. Subgroup analysis was conducted to confirm the 171 association amongst patients with different clinical important predictors accounting to the diabetic and the metabolic profile, as well as the conditions and medications associated with 172

173 prostate diseases. Cause-specific and sub-distribution hazard models were conducted to 174 consider possible competing risks. Multiple propensity adjustment approaches were used, 175 including propensity score stratification [20], propensity score matching with inverse 176 probability of treatment weighting [21] and propensity score matching with stable inverse 177 probability weighting [22]. The three arm sensitivity results involving glucagon-like peptide-1 178 receptor agonist (GLP1a) using stabilized IPTW were conducted to test the association and 179 choice amongst the novel second-line anti-diabetic medications. Patients with CKD stage 4/5 180 (eGFR <30 mL/min/1.73m<sup>2</sup>), peritoneal dialysis or haemodialysis who may be 181 contraindicated with SGLT2I were excluded in the sensitivity analysis. Sensitivity analysis 182 results with consideration of one-year lag time effects was also conducted. The hazard ratio 183 (HR), 95% CI and P-value were reported. Statistical significance was defined as P-value <0.05. 184 All statistical analyses were performed with RStudio (Version: 1.1.456) and Python (Version: 185 3.6), unless otherwise specified.

186

187

#### 188 **Results**

189 Basic characteristics

In this territory-wide cohort study of 42491 male patients with T2DM treated with
SGLT2I or DPP4I between 1st January 2015 and 31st December 2020 in Hong Kong, patients
were followed up until 31st December 2020 or until their deaths (Figure 1). After exclusion,
This cohort comprises 42129 male T2DM patients with a mean age of 61.0 years old (Standard
deviation: 12.2), amongst which 17120 patients used SGLT2Is, and 25009 patients used
DPP4Is.

196 The DPP4I and SGLT2I cohorts were comparable after matching with nearest 197 neighbour search strategy with calliper of 0.1, and the proportional hazard assumption was

198 confirmed (Supplementary Figure 1). After the propensity score matching, the baseline 199 characteristic of the SGLT2I and the DPP4I users were well-balanced, apart from 200 sulphonylurea (SMD=0.17) and thiozolidinedone (SMD=0.11) (Table 1). The 2 unbalanced 201 variables were adjusted in the Cox regression models and were included in the subgroup 202 analysis. In the matched cohort, 162 patients (0.47%) developed new onset prostate cancer. 203 The characteristics of patients are shown in Table 1.

204

205 Primary analysis

206 In the matched cohort, 60 SGLT2I users and 102 DPP4I users developed prostate 207 cancer. In a total of 186869.4 person-year after a follow-up of a median of 5.61 years, the 208 incidence of prostate cancer was lower amongst SGLT2I users (Incidence rate, IR: 0.63; 95% 209 confidence interval, CI: 0. 48-0.81) than in DPP4I (IR: 1.11; CI: 0.90-1.34) users. SGLT2 210 inhibitors users had a 55% lower risk of prostate cancer compared to users of DPP-4 inhibitors 211 after adjustment for demographics, comorbidities, number of prior hospitalisations, medication 212 profile, renal function, glycaemic tests, and the duration of T2DM (HR: 0.45; 95% CI: 0.30-213 0.70, p=0.0003) (Table 2; Figure 2; Supplementary Table 2). This was substantiated by the 214 cumulative incidence curves stratified by SGLT2I versus DPP4I (Figure 2). The marginal 215 effects plots demonstrated that SGLT2I was associated with lower risks of prostate cancer 216 regardless of the duration of the diabetes diagnosis (Supplementary Figure 2), regardless of 217 the number of prior hospitalizations (Supplementary Figure 3).

In a total of 187191.9 person-year, 260 DPP4I and 99 SGLT2I users passed away due to cancer. The incidence of cancer-related mortality was lower amongst SGLT2I users (IR: 1.04; 95% CI: 0.85-1.27) compared to DPP4I users (IR: 2.81; 95% CI: 2.48-3.18). SGLT2I users had a 43% lower risk of cancer-related mortality after adjustment (HR: 0.55; 95% CI: 0.50-0.61, p<0.0001) compared to users of DPP4I. Besides, 1652 DPP4I users and 541 SGLT2I

users passed away. SGLT2I users had a 32% lower risk of all-cause mortality after adjustment
(HR: 0.68; 95% CI: 0.46-0.78, p<0.0001) compared to users of DPP4I (Table 2; Figure 2;</li>
Supplementary Table 2).

226

## 227 Subgroup analysis and sensitivity analysis

228 The results of the subgroup analysis for the effects of SGLT2I and DPP4I on prostate 229 cancer are shown in Figure 3. In the subgroup analysis, the results demonstrated that SGLT2I was associated with lower risks of prostate cancer amongst patients who were older (age >65). 230 231 The results were consistent amongst patients with quartile 2 and 3 HbA1c. Besides, SGLT2I 232 was associated with lower risks of prostate cancer amongst patients without prior heart failure, 233 acute myocardial infarction, atrial fibrillation, peripheral vascular disease, cancer, and renal 234 disease (all p<0.05). Furthermore, SGLT2I had lower risks of prostate cancer amongst patients 235 without using alpha-blockers and antiplatelet (all p<0.05). SGLT2I was also associated with 236 lower risks of prostate cancers amongst patients not on insulin, thiazolidinedione, GLP1a. 237 However, those could be due to the insufficient sample size in the subgroups amongst the 238 patients with the diseases or drug users. SGLT2I was also associated with lower risks of 239 prostate cancer amongst metformin and sulphonylurea users. Indeed, SGLT2I was associated 240 with higher risks of prostate cancer amongst patients without sulphonylurea (HR: 5.55; 95%) 241 CI: 1.26-22.43).

242

### 243 Sensitivity analysis

Sensitivity analyses were performed to confirm the predictability of the models. The results of the cause-specific hazard models, sub-distribution hazard models and different propensity score approaches demonstrated that different models do not change the point

247 estimates for both the primary and the secondary outcomes (all P<0.05) (Supplementary 248 **Table 3).** A 3-arm analysis with the inclusion of GLP1a including patients only on SGLT2I. 249 DPP4I, and GLP1a using stabilized IPTW was conducted (Supplementary Table 4). The 250 results between DPP4I and SGLT2I remained consistent with the main result (all p<0.05) 251 (Table 2). However, it was found that SGLT2I was not associated with lower risks of prostate 252 cancer compared to GLP1a. Excluding patients with CKD stage 4/5 (eGFR <30 mL/min/1.73m<sup>2</sup>), peritoneal dialysis or haemodialysis in the matched cohort likewise 253 254 demonstrated that SGLT2I was associated with lower risks of prostate cancer compared to 255 DPP4I (Supplementary Table 5). Meanwhile, the sensitivity analysis for 1-year lag time also 256 demonstrated the same trend (all p<0.05) (Supplementary Table 6).

257

#### 258 Discussion

In this territory-wide cohort study, we utilised real-world data to compare the association between SGLT2I, DPP4I and new-onset prostate cancer. Our results suggest that SGLT2I usage is associated with a lowered risk of new-onset prostate cancer than DPP4I usage. To the best of our knowledge, this is the first study to directly compare the relative association of two anti-diabetic medications on the incidence of prostate cancer.

264

#### 265 *Comparison with previous studies*

The prevalence of prostate cancer in our study (IR: 86.7; 95% CI: 73.9-101 per 100,000 person-year) is like the existing literature, which described an incidence of 65.1 per 100,000 person-year amongst T2DM patients in the whole China [23-25]. It was believed that T2DM patients are associated with an increased prevalence of prostate cancer and adverse complications [26]. A meta-analysis suggests that diabetic patients are associated with a worse

271 prognosis [27]. On the contrary, some studies show no correlation or even an inverse 272 association between T2DM and prostate cancer [28]. While the relationship between T2DM 273 and prostate cancer remained controversial, the pleiotropic effects of the anti-diabetic drugs 274 may provide us with new insights.

275 In our study, we found that SGLT2I users had 55% relatively lower risks of prostate 276 cancer compared to DPP4I users. In a previous meta-analysis, it was demonstrated that there 277 was no association between SGLT2I use and incidence of overall cancer [29]. A meta-analysis 278 found that DPP4I and SGLT2I show no significant association with prostate cancer compared 279 to placebo, while GLP1a agents demonstrated beneficial effects against prostate cancer [30]. 280 However, the 7 randomised control trials studies included regarding of SGLT2I were posthoc 281 analyses without the primary aim of investigating prostate cancer, and the results demonstrated a relatively high heterogenicity ( $P_{heterogenity} < 0.01$ ,  $I^2 = 97.3\%$ ). The meta-analysis did not 282 283 directly compare the effects between SGLT2I and DPP4I. For the SGLT2I-DPP4I comparison, 284 Rokszin et al. found no significant difference in the risk of prostate cancer (HR: 0.65; 95% CI: 285 0.42-1.02) between the SGLT2I and DPP4I users [12]. However, the difference between the 286 two arms remained worthy of investigation since the upper 95% CI of prostate cancer was close to 1 and that study followed up the patients for two years only, while in our study the follow-287 288 up duration median was 5.61 years.

The investigation of novel anti-diabetic medications was prompted by biological evidence in the current literature that underscores possible pleiotropic effects of SGLT2I and DPP4I on prostate cancer [31-33]. Interest in this area was prompted largely due to the fact that cancer cells utilise glucose as a primary source of fuel rather than fatty acids [34]. Moreover, evidence suggests that SGLT2I usage may inhibit the AMPK/mTOR pathway and induce apoptosis of cancerous cells [35]. Scafoglio *et al.* found abundant functional expression of SGLT2 on prostate adenocarcinomas; thereby inhibition of SGLT2 receptors reduces glucose

296 uptake and tumour progression in a xenograft model [36]. In a cell culture study, it was found 297 that SGLT2I inhibited the clonogenic survival of prostate cancer cells [37]. In our study, the 298 protective effects of SGLT2I were significant amongst patients without comorbidities but not 299 those with prior comorbidities (heart failure, prior acute myocardial infarction, atrial fibrillation, 300 peripheral vascular diseases). On one hand, while this could be explained by the limited sample 301 size in the subgroups, we may also hypothesise that this could be explained partially by the 302 SGLT2 expression level, as systemic diseases were suggested to increase the expression and 303 activity of SGLT2 [38].

304 It must be noted that this does not necessarily mean that DPP4I is harmful in terms of 305 new-onset prostate cancer, but it may as well be protective against prostate cancer compared 306 to non-users. DPP4I and SGLT2I may modulate the risks of developing prostate cancer 307 amongst T2DM patients. For DPP4I, previously, it was found that the use of saxagliptin and 308 exenatide may decrease prostate cancer risk compared to sulfonylurea usage [39]. In another 309 observational study, sitagliptin usage was associated with lower risks of prostate cancer 310 amongst Asians with an odd ratio of 0.61 [40]. In addition, the Liraglutide Effect and Action 311 in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial revealed that 312 malignant prostate neoplasms were present in a lower proportion of diabetic patients who use 313 liraglutide compared to the placebo group [41]. Although the mechanism behind the observed 314 effects of cancer growth inhibition remains ambiguous, the potential implications of SGLT2I 315 and DPP4I usage as a part of cancer treatment continue to be revised in the growing body of 316 literature.

317

318 Clinical implications

319 The potential antineoplastic benefit of SGLT2I and DPP4I on various cancer types have 320 received global interest in recent years. As prostate cancer is one of the leading causes of 321 cancer-related mortality among men, our findings could carry critical clinical implications in 322 optimising treatment for T2DM male patients who might be at higher risk of developing 323 prostate cancer. Thus, future studies in-cooperating randomised clinical trials are essential for clinicians to provide prevention of prostate cancer for diabetic patients. In the long term, this 324 325 can reduce healthcare resource expenditure and refine clinical guidelines that govern treatment 326 for prostate cancer and diabetes. This study has explored the relationship of data obtained from 327 routine clinical practice in Hong Kong. This study suggests that SGLT2I may demonstrate a 328 more significant overall protective effect against prostate cancer compared to DPP4I. 329 Previously, metformin was suggested to be associated with reduced mortality amongst prostate 330 cancer patients independent of diabetic control [42]. As such, SGLT2I may also play a role in 331 altering the cancer outcomes and prognosis amongst prostate cancer patients.

332

#### 333 Limitations

334 Several limitations should be noted in this study. Due to the observational nature of this study variables which predict prostate cancer, such as BMI, alcohol use, smoking, 335 336 socioeconomic status, family history of prostate cancer, and screening PSA level, were not available from CDARS. This was attempted to be addressed by including laboratory results 337 338 and comorbidities to infer the potential risk factors. To further compensate for this, we have 339 matched our drug cohorts over an array of diseases and medications, adjusted the regression, 340 and conducted a range of sensitivity analyses to minimise bias. Besides, there is potential 341 under-coding, coding errors, and missing data leading to information bias due to the nature of 342 the study. Moreover, the patient's level of compliance and drug exposure duration could not 343 be standardised. Lastly, the retrospective design of our study necessitates the presentation of

344	associations but not causal links between SGLT2I versus DPP4I use and the risk of new-onset
345	prostate cancer. Therefore, further research is warranted to explore the beneficial effects of
346	SGLT2I.
347	
348	Conclusion
349	In this population-based cohort study, SGLT2I users were associated with lower risks
350	of new-onset prostate cancer than DPP4I users amongst T2DM patients. These results may
351	have potential clinical implications in preventing cancer among T2DM patients. Further
352	randomised controlled trials and mechanistic studies into prostate cancer with SGLT2I are
353	needed.
354 355	Funding source
356	The authors received no funding for the research, authorship, and/or publication of this
357	article.
358	
359	Conflicts of Interest
360	None.
361	
362	Ethical approval statement
363	This study was approved by the Institutional Review Board of the University of Hong
364	Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250), and
365	New Territories East Cluster-Chinese University of Hong Kong (NTEC-UCHK) Clinical
366	Research Ethnics Committee (2018.309, 2018.643) and complied with the Declaration of
367	Helsinki.

#### 368

## 369 Availability of data and materials

- 370 Data are not available, as the data custodians (the Hospital Authority and the Department of
- 371 Health of Hong Kong SAR) have not given permission for sharing due to patient confidentiality
- 372 and privacy concerns. Local academic institutions, government departments, or
- 373 nongovernmental organizations may apply for the access to data through the Hospital
- 374 Authority's data sharing portal (<u>https://www3.ha.org.hk/data</u>).
- 375

## 376 Acknowledgements

- 377 None.
- 378

## 379 Guarantor Statement

- 380 All authors approved the final version of the manuscript. GT is the guarantor of this work and,
- as such, had full access to all the data in the study and takes responsibility for the integrity of
- 382 the data and the accuracy of the data analysis.

383

## **384 Author contributions**

- 385 Data analysis: OHIC, LL, JZ
- 386 Data review: OHIC, JSKC, RNCC, SL, GT, JZ
- 387 Data acquisition: OHIC, HHHP, SL
- 388 Data interpretation: OHIC, CTC, JSKC, BMYC, GT, JZ
- 389 Critical revision of manuscription: JSKC, RNCC, ALYH, ECD, KN, BMYC, GT, JZ
- 390 Supervision: BMYC, GT, JZ

medRxiv preprint doi: https://doi.org/10.1101/2023.11.25.23298886; this version posted November 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

# 391 Manuscript writing: OHIC, CTC, JSKC, ALYH, KKW

392 Manuscript revision: OHIC, JSKC, ALYH, ECD, KN, BMYC, GT, JZ

393

# **Reference**

- 395
- 396 [1] Maruthur NM. The Growing Prevalence of Type 2 Diabetes: Increased Incidence or
- 397 Improved Survival? Current Diabetes Reports. 2013;13:786-94.
- 398 [2] Leslie SW, Soon-Sutton TL, R IA, Sajjad H, Siref LE. Prostate Cancer. StatPearls.
- 399 Treasure Island (FL): StatPearls Publishing
- 400 Copyright © 2023, StatPearls Publishing LLC.; 2023.
- 401 [3] Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer Incidence and Mortality:
- Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Health.
  2022;10:811044.
- 404 [4] Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, et al. History of diabetes
- 405 mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes & Control.
  406 2010;21:1025-32.
- 407 [5] Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate
- 408 cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151 409 8, s1.
- 410 [6] Chung CT, Lakhani I, Chou OHI, Lee TTL, Dee C, Ng K, et al. Sodium-glucose
- 411 cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer
- 412 in Type 2 diabetes mellitus: A population-based study. Cancer Med. 2023.
- 413 [7] Olokpa E, Mandape SN, Pratap S, Stewart LMV. Metformin regulates multiple signaling
- 414 pathways within castration-resistant human prostate cancer cells. BMC Cancer.
- 415 2022;22:1025.
- 416 [8] Clements A, Gao B, Yeap S, Wong M, Ali S, Gurney H. Metformin in prostate cancer:
- 417 two for the price of one. Annals of oncology. 2011;22:2556-60.
- 418 [9] Lee YHA, Zhou J, Hui JMH, Liu X, Lee TTL, Hui K, et al. Risk of New-Onset Prostate
- 419 Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity
- 420 Score-Matched Study. J Natl Compr Canc Netw. 2022;20:674-82.e15.
- 421 [10] Chen CB, Eskin M, Eurich DT, Majumdar SR, Johnson JA. Metformin, Asian ethnicity
- 422 and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis. Bmc
  423 Cancer. 2018;18:1-7.
- 424 [11] Crunkhorn S. Repurposing SGLT2 inhibitors. Nature Reviews Drug Discovery.
- 425 2019;18:18-.
- 426 [12] Rokszin G, Kiss Z, Sütő G, Kempler P, Jermendy G, Fábián I, et al. Sodium-Glucose
- 427 Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and
- 428 Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of
- 429 the Post-Hoc Analysis of a Nationwide Study. Frontiers in Oncology. 2021;11:725465.
- 430 [13] Lau IT. A Clinical Practice Guideline to Guide a System Approach to Diabetes Care in
- 431 Hong Kong. Diabetes Metab J. 2017;41:81-8.
- 432 [14] Au PCM, Tan KCB, Lam DCL, Cheung BMY, Wong ICK, Kwok WC, et al.
- 433 Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor
- 434 Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among
- 435 Patients With Type 2 Diabetes in Hong Kong. JAMA Netw Open. 2023;6:e2251177.
- 436 [15] Zhou J, Liu X, Chou OH, Li L, Lee S, Wong WT, et al. Lower risk of gout in sodium
- 437 glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors
- 438 in type-2 diabetes. Rheumatology (Oxford). 2023;62:1501-10.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.25.23298886; this version posted November 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

- 439 [16] Chou OHI, Zhou J, V Mui J, Satti DI, Chung CT, Tai Loy Lee T, et al. Lower risks of
- 440 new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2
- 441 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity
- score-matched study with competing risk analysis. Diabetes Epidemiology and Management.
  2023;9:100115.
- 444 [17] Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A
- 445 Critical Review of Clinimetric Properties. Psychother Psychosom. 2022;91:8-35.
- 446 [18] Soliman AR, Fathy A, Khashab S, Shaheen N. Comparison of abbreviated modification
- 447 of diet in renal disease formula (aMDRD) and the Cockroft-Gault adjusted for body surface
- 448 (aCG) equations in stable renal transplant patients and living kidney donors. Ren Fail.449 2013;35:94-7.
- 450 [19] Lau KTK, Wong CKH, Au ICH, Lau WCY, Man KKC, Chui CSL, et al. Switching to
- 451 Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking
- 452 Sodium-Glucose Cotransporter-2 Inhibitors. Journal of the American Heart Association.
   453 2022;11:e023489.
- 454 [20] Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
- 455 Confounding in Observational Studies. Multivariate Behav Res. 2011;46:399-424.
- 456 [21] Austin PC, Stuart EA. Moving towards best practice when using inverse probability of
- treatment weighting (IPTW) using the propensity score to estimate causal treatment effects inobservational studies. Stat Med. 2015;34:3661-79.
- 459 [22] Avagyan V, Vansteelandt S. Stable inverse probability weighting estimation for
- 460 longitudinal studies. Scandinavian Journal of Statistics. 2021;48:1046-67.
- 461 [23] Zhang L, Yang BX, Zhang HT, Wang JG, Wang HL, Zhao XJ. Prostate cancer: an
- 462 emerging threat to the health of aging men in Asia. Asian J Androl. 2011;13:574-8.
- 463 [24] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
- 464 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
- 465 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71:209-49.
- 466 [25] Gu Y, Hou X, Zheng Y, Wang C, Zhang L, Li J, et al. Incidence and Mortality Risks of
- 467 Cancer in Patients with Type 2 Diabetes: A Retrospective Study in Shanghai, China. Int J
- 468 Environ Res Public Health. 2016;13.
- 469 [26] Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality
- 470 after incident cancer in people with and without type 2 diabetes: impact of metformin on
- 471 survival. Diabetes care. 2012;35:299-304.
- [27] Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: a
   meta-analysis. Springerplus. 2016;5:1548.
- 474 [28] Feng X, Song M, Preston MA, Ma W, Hu Y, Pernar CH, et al. The association of
- 475 diabetes with risk of prostate cancer defined by clinical and molecular features. British
- 476 Journal of Cancer. 2020;123:657-65.
- 477 [29] Pelletier R, Ng K, Alkabbani W, Labib Y, Mourad N, Gamble JM. The association of
- 478 sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative
- 479 systematic reviews. Endocrinol Diabetes Metab. 2020;3:e00145.
- 480 [30] Cui H, Wang Y, Yang S, He G, Jiang Z, Gang X, et al. Antidiabetic medications and the
- risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta analysis. Pharmacological Research. 2022:106094.
- 483 [31] Lu Z, Qi L, Bo XJ, Liu GD, Wang JM, Li G. Expression of CD26 and CXCR4 in
- 484 prostate carcinoma and its relationship with clinical parameters. J Res Med Sci. 2013;18:647485 52.
- 486 [32] Bekele K, Smith T, Stewart L. The SGLT2 Inhibitor Canagliflozin Reduces Androgen
- 487 Receptor Expression and Nuclear Localization of Beta-Catenin in Human Prostate Cancer
- 488 Cells. 2022.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.25.23298886; this version posted November 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 489 [33] Benedetti R, Benincasa G, Glass K, Chianese U, Vietri MT, Congi R, et al. Effects of
- 490 novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of
- 491 randomized clinical trials. Pharmacological Research. 2022;175:106039.
- 492 [34] Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of
- 493 canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells:
- 494 Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
- 495 PLoS One. 2020;15:e0232283.
- 496 [35] Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, et al. Sodium-glucose co-transporter-2
- 497 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest
- 498 through AMPK/mTOR pathway. Biomed Pharmacother. 2020;132:110821.
- 499 [36] Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional
- 500 expression of sodium-glucose transporters in cancer. Proceedings of the National Academy of 501 Sciences. 2015;112:E4111-E9.
- 502 [37] Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, et al. The
- 503 diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting
- 504 mitochondrial complex-I supported respiration. Molecular metabolism. 2016;5:1048-56.
- 505 [38] Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose
- 506 Linked Transporter 2) Inhibitors. Hypertension. 2020;75:894-901.
- 507 [39] Lu S, Yin H, Yu OHY, Azoulay L. Incretin-Based Drugs and the Incidence of Prostate
- 508 Cancer Among Patients With Type 2 Diabetes. Epidemiology. 2022;33:563-71.
- 509 [40] Tseng CH. Sitagliptin may reduce prostate cancer risk in male patients with type 2
- 510 diabetes. Oncotarget. 2017;8:19057-64.
- 511 [41] Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms Reported With
- 512 Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER
- 513 Randomized Trial. Diabetes Care. 2018;41:1663-71.
- 514 [42] Lee YHA, Hui JMH, Chan JSK, Liu K, Dee EC, Ng K, et al. Metformin use and
- 515 mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A
- 516 population-based study. Prostate. 2023;83:119-27.
- 517
- 518
- 519
- 520

# Table 1. Baseline and clinical characteristics of patients with SGLT2I v.s. DPP4I use before and after propensity score matching (1:1).

\* for SMD≥0.1; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers.

	Before matching					After matching		
Characteristics	All (N=42129) Mean(SD);N or Count(%)	SGLT2I (N=17120) Mean(SD);N or Count(%)	DPP4I (N=25009) Mean(SD);N or Count(%)	SMD	All (N=34240) Mean(SD);N or Count(%)	SGLT2I (N=17120) Mean(SD);N or Count(%)	DPP4I (N=17120) Mean(SD);N or Count(%)	SMD
Demographics								
Baseline age, years	61.0(12.2);n=42129	57.3(10.9);n=17120	63.5(12.4);n=25009	0.53*	57.7(10.7);n=34240	57.3(10.9);n=17120	58.2(10.5);n=17120	0.08
Past comorbidities								
Charlson standard comorbidity index	1.9(1.5);n=42129	1.5(1.2);n=17120	2.2(1.6);n=25009	0.47*	1.5(1.2);n=34240	1.5(1.2);n=17120	1.6(1.2);n=17120	0.05
Duration from earliest diabetes mellitus diagnosis date to baseline date, years	6.5(4.9);n=42129	6.8(4.9);n=17120	6.3(4.9);n=25009	0.1	6.7(5.0);n=34240	6.8(4.9);n=17120	6.5(5.1);n=17120	0.07
Number of prior hospitalizations	1.2(0.8);n=42129	1.3(1.1);n=17120	1.2(0.6);n=25009	0.17	1.3(1.0);n=34240	1.3(1.1);n=17120	1.2(0.9);n=17120	0.08
Hyperlipidaemia	30441(72.25%)	12812(74.83%)	17629(70.49%)	0.1	25853(75.50%)	12812(74.83%)	13041(76.17%)	0.03
Hypertension	25490(60.50%)	15280(89.25%)	10210(40.82%)	1.18*	24440(71.37%)	12280(71.72%)	12160(71.02%)	0.02
Urinary tract infection	1493(3.54%)	415(2.42%)	1078(4.31%)	0.1	807(2.35%)	415(2.42%)	392(2.28%)	0.01
Cancer	731(1.73%)	209(1.22%)	522(2.08%)	0.07	415(1.21%)	209(1.22%)	206(1.20%)	<0.01
Autoimmune disease	e 330(0.78%)	137(0.80%)	193(0.77%)	<0.01	272(0.79%)	137(0.80%)	135(0.78%)	<0.01
Heart failure	1328(3.15%)	495(2.89%)	833(3.33%)	0.03	979(2.85%)	495(2.89%)	484(2.82%)	<0.01
lschemic heart disease	5200(12.34%)	2677(15.63%)	2523(10.08%)	0.17	5013(14.64%)	2577(15.05%)	2436(14.22%)	0.02
Acute myocardial infarction	1541(3.65%)	771(4.50%)	770(3.07%)	0.07	1513(4.41%)	771(4.50%)	742(4.33%)	0.01

Peripheral vascular disease	341(0.80%)	98(0.57%)	243(0.97%)	0.05	196(0.57%)	98(0.57%)	98(0.57%)	<0.01
Atrial fibrillation	993(2.35%)	370(2.16%)	623(2.49%)	0.02	724(2.11%)	370(2.16%)	354(2.06%)	0.01
Stroke/transient ischemic attack	1259(2.98%)	423(2.47%)	836(3.34%)	0.05	836(2.44%)	423(2.47%)	413(2.41%)	<0.01
Diabetic retinopathy	2723(6.46%)	1019(5.95%)	1704(6.81%)	0.04	1926(5.62%)	1019(5.95%)	907(5.29%)	0.03
Diabetic nephropathy	528(1.25%)	116(0.67%)	412(1.64%)	0.09	232(0.67%)	116(0.67%)	116(0.67%)	<0.01
Diabetic neuropathy	872(2.06%)	311(1.81%)	561(2.24%)	0.03	601(1.75%)	311(1.81%)	290(1.69%)	0.01
Renal diseases	3269(7.75%)	899(5.25%)	2370(9.47%)	0.16	1704(4.97%)	899(5.25%)	805(4.70%)	0.03
Liver diseases	1741(4.13%)	807(4.71%)	934(3.73%)	0.05	1520(4.43%)	807(4.71%)	713(4.16%)	0.03
Chronic obstructive pulmonary disease	466(1.10%)	122(0.71%)	344(1.37%)	0.07	243(0.70%)	122(0.71%)	121(0.70%)	<0.01
Medications								
Number of anti- diabetic drugs	9.5(26.7);n=42129	12.7(32.8);n=17120	7.3(21.3);n=25009	0.2	12.7(32.8);n=34240	12.7(32.8);n=17120	12.8(32.7);n=17120	<0.01
Metformin	37650(89.36%)	15922(93.00%)	21728(86.88%)	0.20*	31909(93.19%)	15922(93.00%)	15987(93.38%)	0.02
Sulphonylurea	32456(77.03%)	12393(72.38%)	20063(80.22%)	0.19	26040(76.05%)	12393(72.38%)	13647(79.71%)	0.17*
Insulin	21040(49.94%)	8455(49.38%)	12585(50.32%)	0.02	16773(48.98%)	8455(49.38%)	8318(48.58%)	0.02
Acarbose	1402(3.32%)	640(3.73%)	762(3.04%)	0.04	1235(3.60%)	640(3.73%)	595(3.47%)	0.01
Thiazolidinedione	8506(20.19%)	4448(25.98%)	4058(16.22%)	0.24*	8131(23.74%)	4448(25.98%)	3683(21.51%)	0.11*
Glucagon-like								
peptide-1 receptor agonists	2666(6.32%)	1159(6.76%)	1507(6.02%)	0.03	2250(6.57%)	1159(6.76%)	1091(6.37%)	0.02
Statins and fibrates	26683(63.33%)	12716(74.27%)	13967(55.84%)	0.39*	25225(73.67%)	12716(74.27%)	12509(73.06%)	0.03
ACEI/ARB	22307(52.94%)	10563(61.69%)	11744(46.95%)	0.30*	21120(61.68%)	10563(61.69%)	10557(61.66%)	<0.01
Diuretics	12276(29.13%)	5536(32.33%)	6740(26.95%)	0.12	11411(33.32%)	5536(32.33%)	5875(34.31%)	0.04
Beta-blockers	11878(28.19%)	5048(29.48%)	6830(27.31%)	0.05	10565(30.85%)	5048(29.48%)	5517(32.22%)	0.06

Calcium channel								
blockers (dibudropyriding)	21531(51.10%)	9919(57.93%)	11612(46.43%)	0.23*	19921(58.18%)	9919(57.93%)	10002(58.42%)	0.01
(uniyuropynume) Calcium channel								
blocker (non-	11656(27.66%)	5014(29.28%)	6642(26.55%)	0.06	9795(28.60%)	5014(29.28%)	4781(27.92%)	0.03
dihydropyridine)	· · ·		, , , , , , , , , , , , , , , , , , ,			· · ·	· · ·	
Systemic steroids	269(0.63%)	126(0.73%)	143(0.57%)	0.02	252(0.73%)	126(0.73%)	126(0.73%)	<0.01
Antiplatelets	13825(32.81%)	6401(37.38%)	7424(29.68%)	0.16	12869(37.58%)	6401(37.38%)	6468(37.78%)	0.01
Alpha-blockers	7488(17.77%)	2624(15.32%)	4864(19.44%)	0.11	5033(14.69%)	2624(15.32%)	2409(14.07%)	0.04
Aspirin	12408(29.45%)	5963(34.83%)	6445(25.77%)	0.2	11902(34.76%)	5963(34.83%)	5939(34.69%)	<0.01
Calculated biomarker								
Abbreviated MDRD, mL/min/1.73m^2	80.8(26.9);n=34221	88.6(22.6);n=14077	75.4(28.3);n=20144	0.51*	87.5(23.2);n=28366	88.6(22.6);n=14077	86.4(23.7);n=14289	0.09
Renal function tests								
Creatinine, umol/L	103.7(79.5);n=34221	87.9(29.0);n=14077	114.8(99.2);n=20144	0.37*	89.7(37.2);n=28366	87.9(29.0);n=14077	91.4(43.8);n=14289	0.09
Lipid tests								
Triglyceride, mmol/L	1.7(1.8);n=32353	1.9(2.0);n=13493	1.7(1.6);n=18860	0.1	1.9(2.0);n=27134	1.85(1.96);n=13493	1.87(2.08);n=13641	0.01
Low-density lipoprotein, mmol/L	2.4(0.8);n=31726	2.3(0.8);n=13219	2.4(0.8);n=18507	0.04	2.4(0.8);n=26546	2.3(0.8);n=13219	2.4(0.8);n=13327	0.05
High-density lipoprotein, mmol/L	1.1(0.3);n=32298	1.09(0.28);n=13468	1.14(0.31);n=18830	0.14	1.1(0.3);n=27093	1.09(0.28);n=13468	1.1(0.29);n=13625	0.04
Total cholesterol, mmol/L	4.2(1.0);n=32387	4.22(1.01);n=13510	4.23(0.99);n=18877	0.01	4.3(1.0);n=27166	4.2(1.0);n=13510	4.3(1.0);n=13656	0.06
Glucose tests								
Haemoglobin A1C, %	8.1(1.6);n=33538	8.3(1.6);n=13824	8.0(1.6);n=19714	0.18	8.3(1.6);n=27789	8.25(1.61);n=13824	8.26(1.58);n=13965	0.01
Fasting glucose, mmol/L	9.0(3.9);n=30477	9.2(3.6);n=12691	8.8(4.2);n=17786	0.08	9.2(3.8);n=25612	9.2(3.6);n=12691	9.3(4.1);n=12921	0.04

# Table 2. Incidence rate (IR) per 1000 person-year of new onset prostate cancer, cancerrelated mortality, and all-cause mortality in the cohort before and after 1:1 propensity score matching.

SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease

Adjusted for significant demographics, past comorbidities, duration of diabetes mellitus, number of prior hospitalizations, number of anti-diabetic drugs, non-SGLT2I/DPP4I medications, abbreviated MDRD, HbA1c, fasting glucose.

Prostate	Number of	Number	Total	Follow-up	Incidence	Adjusted	P-value
cancer	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
			year	[95% CI]		[95% CI]	
DPP4I	17120	102	92074.6	5.6 [5.31-5.83]	1.11[0.90-	1 [reference]	NA
					1.34]		
SGLT2I	17120	60	94794.8	5.62 [5.35-5.83]	0.63[0.48-	0.45[0.30-0.70]	0.0003
					0.81]		
Cancer-	Number of	Number	Total	Follow-up	Incidence	Adjusted	P value
related	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
mortality			year	[95% CI]		[95% CI]	
DPP4I	17120	260	92299.7	5.6 [5.31-5.83]	2.81[2.48-	1 [reference]	NA
					3.18]		
SGLT2I	17120	99	94892.2	5.62 [5.33-5.82]	1.04[0.85-	0.57[0.40-0.76]	<0.0001
					1.27]		
All-cause	Number of	Number	Total	Follow-up	Incidence	Adjusted	P value
mortality	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
			year	[95% CI]		[95% CI]	
DPP4I	17120	1652	92299.7	5.6 [5.31-5.83]	17.9[17.0-	1 [reference]	NA
					18.8]		
SGLT2I	17120	E/11	94892.2	5.62 [5.35-5.82]	5.70[5.23-	0.68[0.46-0.78]	<0.0001
		541			6.20]		







## Figure 1. Procedures of data processing for the study cohort

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors. MDRD: modification of diet in renal disease.





Figure 2. Cumulative incidence curves for new onset prostate cancer, cancer-related mortality, and all-cause mortality stratified by drug exposure effects of SGLT2I and DPP4I after propensity score matching (1:1).

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors

Variables			Prostate cancer	Hacard ratio [95% Cl]; P-value
Demographics	Age <65	-	⊢ <b>-</b> 1	0.65[0.31-1.37];0.2557
	Age >65	-	<b>⊢</b> →→→	0.44[0.26-0.77];0.0036**
Metabolic	Hypertension	-	<b>⊢_</b> •I	1.10[0.68-1.76];0.7060
	No hypertension	-	<b>⊢</b> →→,	0.39[0.24-0.62];0.0001***
	Hyperlipidaemia	-	⊢ <b>↓</b>	0.62[0.43-0.88];0.0077**
	No hyperlipidaemia	-	<b>⊢</b> ••-1	0.67[0.31-1.47];0.3212
HbA1c	Q1 HbA1c	-	·	0.91[0.39-2.09];0.8190
	Q2 HbA1c	-	<b>⊢</b>	0.42[0.19-0.95];0.0371*
	Q3 HbA1c	-	⊢ <b>−−</b> −−	0.34[0.14-0.86];0.0217*
	Q4 HbA1c	-		-
Comorbidities	Heart failure	-	<u>н на конструкција</u> на конструкција на конструкција На конструкција на конструкција на конструкција на конструкција на конструкција на конструкција на конструкција н	0.96[0.19-4.76];0.9606
	No heart failure	-	⊢ <b>→</b>	0.61[0.44-0.85];0.0036**
History	y of acute myocardial infarction	-	↓ <b>↓</b>	0.36[0.09-1.35];0.1281
No history	y of acute myocardial infarction	-	<b>⊢</b> •−1	0.65[0.46-0.90];0.0108*
	Atrial fibrillation	-	· · · · · · · · · · · · · · · · · · ·	1.88[0.47-7.50];0.3734
	No atrial fibrillation	-	<b>⊢</b> →−1	0.58[0.41-0.81];0.0015**
	Peripheral vascular disease	-	·	1.92[0.17-21.16];0.5948
Ν	lo peripheral vascular disease	-	<b>⊢</b> •−-	0.61[0.44-0.84];0.0030**
	Cancer	-	·	0.13[0.02-1.08];0.0590
	No cancer	-	<b>⊢</b> •	0.66[0.48-0.92];0.0142*
	Renal disease	-	·	2.56[0.83-7.94];0.1037
	No renal disease	-	<b>⊢</b> •−-1	0.52[0.37-0.74];0.0003***
	Liver disease	-		0.11[0.01-0.84];0.0340*
	No liver disease	-	<b>⊢</b> •i	0.67[0.48-0.94];0.0192*
Drugs	Alpha-blocker	-	⊢ <u>∔</u> ∙	1.18[0.60-2.30];0.6357
	No alpha-blocker	-	<b>⊢</b> •−1	0.50[0.34-0.73];0.0004***
	Insulin	-	, <b>+</b>	0.78[0.50-1.23];0.2905
	No insulin	-	<b>⊢</b> •−→	0.49[0.31-0.78];0.0030**
	Metformin	-	<b>⊢</b> •−-1	0.59[0.42-0.83];0.0025**
	No metformin	-	·	0.95[0.32-2.83];0.9260
	Sulphonylurea	-	<b>⊢</b> →−1	0.52[0.37-0.75];0.0003***
	No sulphonylurea	-	ļ•	5.55[1.26-24.43];0.0234*
	Thiozolidinedone	-	·	1.89[0.66-5.43];0.2386
	No thiozolidinedone	4	<b>⊢</b> •−1	0.56[0.40-0.80];0.0012**
	GLP-1 agonist	-	⊢ <b>-</b>	1.59[0.14-17.56];0.7041
	No GLP-1 agonist	4	<b>⊢</b> →−1	0.61[0.44-0.85];0.0035**
	Anti-platelet	4	, <b></b> ∎	0.54[0.27-1.07];0.0769
	No anti-platelet	-	⊢ŧ	0.65[0.45-0.94];0.0227*
		0.01	0.1 1	10
		0.01	Hazard ratio [95% CI]	
		-	Favour SGLT2I Favour D	)PP4I

# Figure 3. Subgroup analyses for SGLT2I v.s. DPP4I exposure predict prostate cancer in the matched cohort.

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors.Q1: Quartile 1Q2: Quartile 2; Q3: Quartile 3; Q4: Quartile 4; CI: Confidence interval

# Table 1. Baseline and clinical characteristics of patients with SGLT2I v.s. DPP4I use before and after propensity score matching (1:1).

\* for SMD≥0.1; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers.

	Before matching					After matching		
Characteristics	All (N=42129) Mean(SD);N or Count(%)	SGLT2I (N=17120) Mean(SD);N or Count(%)	DPP4I (N=25009) Mean(SD);N or Count(%)	SMD	All (N=34240) Mean(SD);N or Count(%)	SGLT2I (N=17120) Mean(SD);N or Count(%)	DPP4I (N=17120) Mean(SD);N or Count(%)	SMD
Demographics								
Baseline age, years	61.0(12.2);n=42129	57.3(10.9);n=17120	63.5(12.4);n=25009	0.53*	57.7(10.7);n=34240	57.3(10.9);n=17120	58.2(10.5);n=17120	0.08
Past comorbidities								
Charlson standard comorbidity index	1.9(1.5);n=42129	1.5(1.2);n=17120	2.2(1.6);n=25009	0.47*	1.5(1.2);n=34240	1.5(1.2);n=17120	1.6(1.2);n=17120	0.05
Duration from earliest diabetes mellitus diagnosis date to baseline date, years	6.5(4.9);n=42129	6.8(4.9);n=17120	6.3(4.9);n=25009	0.1	6.7(5.0);n=34240	6.8(4.9);n=17120	6.5(5.1);n=17120	0.07
Number of prior hospitalizations	1.2(0.8);n=42129	1.3(1.1);n=17120	1.2(0.6);n=25009	0.17	1.3(1.0);n=34240	1.3(1.1);n=17120	1.2(0.9);n=17120	0.08
Hyperlipidaemia	30441(72.25%)	12812(74.83%)	17629(70.49%)	0.1	25853(75.50%)	12812(74.83%)	13041(76.17%)	0.03
Hypertension	25490(60.50%)	15280(89.25%)	10210(40.82%)	1.18*	24440(71.37%)	12280(71.72%)	12160(71.02%)	0.02
Urinary tract infection	1493(3.54%)	415(2.42%)	1078(4.31%)	0.1	807(2.35%)	415(2.42%)	392(2.28%)	0.01
Cancer	731(1.73%)	209(1.22%)	522(2.08%)	0.07	415(1.21%)	209(1.22%)	206(1.20%)	<0.01
Autoimmune disease	e 330(0.78%)	137(0.80%)	193(0.77%)	<0.01	272(0.79%)	137(0.80%)	135(0.78%)	<0.01
Heart failure	1328(3.15%)	495(2.89%)	833(3.33%)	0.03	979(2.85%)	495(2.89%)	484(2.82%)	<0.01
lschemic heart disease	5200(12.34%)	2677(15.63%)	2523(10.08%)	0.17	5013(14.64%)	2577(15.05%)	2436(14.22%)	0.02
Acute myocardial infarction	1541(3.65%)	771(4.50%)	770(3.07%)	0.07	1513(4.41%)	771(4.50%)	742(4.33%)	0.01

Peripheral vascular disease	341(0.80%)	98(0.57%)	243(0.97%)	0.05	196(0.57%)	98(0.57%)	98(0.57%)	<0.01
Atrial fibrillation	993(2.35%)	370(2.16%)	623(2.49%)	0.02	724(2.11%)	370(2.16%)	354(2.06%)	0.01
Stroke/transient ischemic attack	1259(2.98%)	423(2.47%)	836(3.34%)	0.05	836(2.44%)	423(2.47%)	413(2.41%)	<0.01
Diabetic retinopathy	2723(6.46%)	1019(5.95%)	1704(6.81%)	0.04	1926(5.62%)	1019(5.95%)	907(5.29%)	0.03
Diabetic nephropathy	528(1.25%)	116(0.67%)	412(1.64%)	0.09	232(0.67%)	116(0.67%)	116(0.67%)	<0.01
Diabetic neuropathy	872(2.06%)	311(1.81%)	561(2.24%)	0.03	601(1.75%)	311(1.81%)	290(1.69%)	0.01
Renal diseases	3269(7.75%)	899(5.25%)	2370(9.47%)	0.16	1704(4.97%)	899(5.25%)	805(4.70%)	0.03
Liver diseases	1741(4.13%)	807(4.71%)	934(3.73%)	0.05	1520(4.43%)	807(4.71%)	713(4.16%)	0.03
Chronic obstructive pulmonary disease	466(1.10%)	122(0.71%)	344(1.37%)	0.07	243(0.70%)	122(0.71%)	121(0.70%)	<0.01
Medications								
Number of anti- diabetic drugs	9.5(26.7);n=42129	12.7(32.8);n=17120	7.3(21.3);n=25009	0.2	12.7(32.8);n=34240	12.7(32.8);n=17120	12.8(32.7);n=17120	<0.01
Metformin	37650(89.36%)	15922(93.00%)	21728(86.88%)	0.20*	31909(93.19%)	15922(93.00%)	15987(93.38%)	0.02
Sulphonylurea	32456(77.03%)	12393(72.38%)	20063(80.22%)	0.19	26040(76.05%)	12393(72.38%)	13647(79.71%)	0.17*
Insulin	21040(49.94%)	8455(49.38%)	12585(50.32%)	0.02	16773(48.98%)	8455(49.38%)	8318(48.58%)	0.02
Acarbose	1402(3.32%)	640(3.73%)	762(3.04%)	0.04	1235(3.60%)	640(3.73%)	595(3.47%)	0.01
Thiazolidinedione	8506(20.19%)	4448(25.98%)	4058(16.22%)	0.24*	8131(23.74%)	4448(25.98%)	3683(21.51%)	0.11*
Glucagon-like								
peptide-1 receptor agonists	2666(6.32%)	1159(6.76%)	1507(6.02%)	0.03	2250(6.57%)	1159(6.76%)	1091(6.37%)	0.02
Statins and fibrates	26683(63.33%)	12716(74.27%)	13967(55.84%)	0.39*	25225(73.67%)	12716(74.27%)	12509(73.06%)	0.03
ACEI/ARB	22307(52.94%)	10563(61.69%)	11744(46.95%)	0.30*	21120(61.68%)	10563(61.69%)	10557(61.66%)	<0.01
Diuretics	12276(29.13%)	5536(32.33%)	6740(26.95%)	0.12	11411(33.32%)	5536(32.33%)	5875(34.31%)	0.04
Beta-blockers	11878(28.19%)	5048(29.48%)	6830(27.31%)	0.05	10565(30.85%)	5048(29.48%)	5517(32.22%)	0.06

Calcium channel	21521/51 100/)	0010/57 02%)	11612(46 420/)	∩ <b>ว</b> ว*	10021/59 199/)	0010/57 02%)	10002(58,42%)	0.01
(dihydropyridine)	21551(51.10%)	9919(57.95%)	11012(40.45%)	0.25	19921(38.18%)	9919(57.95%)	10002(58.42%)	0.01
Calcium channel								
blocker (non-	11656(27.66%)	5014(29.28%)	6642(26.55%)	0.06	9795(28.60%)	5014(29.28%)	4781(27.92%)	0.03
dihydropyridine)								
Systemic steroids	269(0.63%)	126(0.73%)	143(0.57%)	0.02	252(0.73%)	126(0.73%)	126(0.73%)	<0.01
Antiplatelets	13825(32.81%)	6401(37.38%)	7424(29.68%)	0.16	12869(37.58%)	6401(37.38%)	6468(37.78%)	0.01
Alpha-blockers	7488(17.77%)	2624(15.32%)	4864(19.44%)	0.11	5033(14.69%)	2624(15.32%)	2409(14.07%)	0.04
Aspirin	12408(29.45%)	5963(34.83%)	6445(25.77%)	0.2	11902(34.76%)	5963(34.83%)	5939(34.69%)	<0.01
Calculated biomarker								
Abbreviated MDRD, mL/min/1.73m^2	80.8(26.9);n=34221	88.6(22.6);n=14077	75.4(28.3);n=20144	0.51*	87.5(23.2);n=28366	88.6(22.6);n=14077	86.4(23.7);n=14289	0.09
Renal function tests								
Creatinine, umol/L	103.7(79.5);n=34221	87.9(29.0);n=14077	114.8(99.2);n=20144	0.37*	89.7(37.2);n=28366	87.9(29.0);n=14077	91.4(43.8);n=14289	0.09
Lipid tests								
Triglyceride, mmol/L	1.7(1.8);n=32353	1.9(2.0);n=13493	1.7(1.6);n=18860	0.1	1.9(2.0);n=27134	1.85(1.96);n=13493	1.87(2.08);n=13641	0.01
Low-density lipoprotein, mmol/L	2.4(0.8);n=31726	2.3(0.8);n=13219	2.4(0.8);n=18507	0.04	2.4(0.8);n=26546	2.3(0.8);n=13219	2.4(0.8);n=13327	0.05
High-density lipoprotein, mmol/L	1.1(0.3);n=32298	1.09(0.28);n=13468	1.14(0.31);n=18830	0.14	1.1(0.3);n=27093	1.09(0.28);n=13468	1.1(0.29);n=13625	0.04
Total cholesterol, mmol/L	4.2(1.0);n=32387	4.22(1.01);n=13510	4.23(0.99);n=18877	0.01	4.3(1.0);n=27166	4.2(1.0);n=13510	4.3(1.0);n=13656	0.06
Glucose tests								
Haemoglobin A1C, %	8.1(1.6);n=33538	8.3(1.6);n=13824	8.0(1.6);n=19714	0.18	8.3(1.6);n=27789	8.25(1.61);n=13824	8.26(1.58);n=13965	0.01
Fasting glucose, mmol/L	9.0(3.9);n=30477	9.2(3.6);n=12691	8.8(4.2);n=17786	0.08	9.2(3.8);n=25612	9.2(3.6);n=12691	9.3(4.1);n=12921	0.04

# Table 2. Incidence rate (IR) per 1000 person-year of new onset prostate cancer, cancerrelated mortality, and all-cause mortality in the cohort before and after 1:1 propensity score matching.

SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease

Adjusted for significant demographics, past comorbidities, duration of diabetes mellitus, number of prior hospitalizations, number of anti-diabetic drugs, non-SGLT2I/DPP4I medications, abbreviated MDRD, HbA1c, fasting glucose.

Prostate	Number of	Number	Total	Follow-up	Incidence	Adjusted	P-value
cancer	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
			year	[95% CI]		[95% CI]	
DPP4I	17120	102	92074.6	5.6 [5.31-5.83]	1.11[0.90-	1 [reference]	NA
					1.34]		
SGLT2I	17120	60	94794.8	5.62 [5.35-5.83]	0.63[0.48-	0.45[0.30-0.70]	0.0003
					0.81]		
Cancer-	Number of	Number	Total	Follow-up	Incidence	Adjusted	P value
related	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
mortality			year	[95% CI]		[95% CI]	
DPP4I	17120	260	92299.7	5.6 [5.31-5.83]	2.81[2.48-	1 [reference]	NA
					3.18]		
SGLT2I	17120	99	94892.2	5.62 [5.33-5.82]	1.04[0.85-	0.57[0.40-0.76]	<0.0001
					1.27]		
All-cause	Number of	Number	Total	Follow-up	Incidence	Adjusted	P value
mortality	patients	of events	person-	duration, years	[95% CI]	hazard ratio	
			year	[95% CI]		[95% CI]	
DPP4I	17120	1652	92299.7	5.6 [5.31-5.83]	17.9[17.0-	1 [reference]	NA
					18.8]		
SGLT2I	17120	F / 1	94892.2	5.62 [5.35-5.82]	5.70[5.23-	0.68[0.46-0.78]	<0.0001
		541			6.20]		